Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $34.88 Consensus Target Price from Analysts

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have been given a consensus recommendation of “Moderate Buy” by the eleven brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $34.8750.

A number of equities research analysts have issued reports on AVTX shares. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Avalo Therapeutics in a research report on Thursday, January 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. Guggenheim initiated coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They issued a “buy” rating and a $50.00 target price on the stock. Finally, Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th.

Avalo Therapeutics Stock Performance

AVTX opened at $15.97 on Friday. The company has a market cap of $295.60 million, a PE ratio of -2.98 and a beta of 0.88. The stock has a 50-day moving average of $16.38 and a 200-day moving average of $14.60. Avalo Therapeutics has a 52-week low of $3.39 and a 52-week high of $20.72.

Institutional Trading of Avalo Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AVTX. Velan Capital Investment Management LP raised its position in shares of Avalo Therapeutics by 38.4% during the second quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company’s stock valued at $773,000 after buying an additional 43,000 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in Avalo Therapeutics during the second quarter worth about $55,000. Aberdeen Group plc increased its stake in Avalo Therapeutics by 31.1% during the fourth quarter. Aberdeen Group plc now owns 95,426 shares of the company’s stock valued at $1,733,000 after acquiring an additional 22,626 shares during the period. PFS Partners LLC raised its holdings in Avalo Therapeutics by 100.0% in the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Cantor Fitzgerald L. P. bought a new stake in shares of Avalo Therapeutics in the 3rd quarter worth approximately $1,083,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.